C4 Therapeutics (CCCC) Return on Sales (2019 - 2026)

C4 Therapeutics' Return on Sales history runs 8 years deep, the most recent figure standing at 0.04% for Q1 2026.

• On a quarterly basis, Return on Sales fell 1.0% year-over-year to 0.04% in Q1 2026; TTM through Mar 2026 was 0.03%, a 0.0% change from a year earlier, with the FY2025 full-year figure at 0.03%, changed 0.0% from the prior year.
• Return on Sales slipped to 0.04% in Q1 2026 per CCCC's latest filing, from 0.02% in the prior quarter.
• Across five years, Return on Sales topped out at 0.01% in Q2 2024 and bottomed at 0.13% in Q2 2023.
• The 5-year median for Return on Sales is 0.04% (2026), against an average of 0.06%.
• Across the five-year window, Return on Sales declined 12 bps in 2022 and rose 12 bps in 2024, its largest moves.
• Year by year, Return on Sales stood at 0.13% in 2022, then climbed by 18 bps to 0.11% in 2023, then jumped by 37 bps to 0.07% in 2024, then soared by 72 bps to 0.02% in 2025, then sank by 141 bps to 0.04% in 2026.
• Per Business Quant, the three latest CCCC Return on Sales figures stand at 0.04% (Q1 2026), 0.02% (Q4 2025), and 0.03% (Q3 2025).